Effects of a transdiagnostic group treatment for anxiety on secondary depression
β Scribed by Peter J. Norton; Sarah A. Hayes; Debra A. Hope
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 111 KB
- Volume
- 20
- Category
- Article
- ISSN
- 1091-4269
- DOI
- 10.1002/da.20045
No coin nor oath required. For personal study only.
β¦ Synopsis
Researchers have recently explored transdiagnostic anxiety treatments based on models of anxiety emphasizing a single common pathway across diagnostic categories. Results from a previous study [Norton and Hope, in press] indicated that a transdiagnostic approach was effective for both targeted and untargeted anxiety disorders. Consistent with the tripartite model, the transdiagnostic treatment should also influence symptoms of a broader pathology such as negative affectivity. This follow-up to Norton and Hope found significant decreases in depressed mood for clients undergoing transdiagnostic treatment for anxiety when compared to wait-list control participants. Although not statistically established, severity of depressive diagnoses seemed to generally decrease across treatment, whereas no change in severity occurred for those not receiving treatment. Depression and Anxiety 20:198-202, 2004. & 2005 Wiley-Liss, Inc.
π SIMILAR VOLUMES
## Abstract Paroxetine is a potent selective serotonin reuptake inhibitor (SSRI) with indications for the treatment of depression, obsessiveβ compulsive disorder, panic disorder and social phobia. It is also used in the treatment of generalized anxiety disorder, postβtraumatic stress disorder, prem